Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Launched by M.D. ANDERSON CANCER CENTER · Feb 2, 2021

Keywords

ClinConnect Summary

The MiRDA-C Study is a clinical trial aimed at understanding if certain molecules, like circulating tumor DNA (ctDNA), found in the blood can help doctors predict if colorectal cancer might come back or spread. When tumors grow, they release tiny bits of DNA and other substances into the bloodstream. By studying these, researchers hope to gain insights that could guide future treatments and monitoring for patients with colorectal cancer.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of colorectal adenocarcinoma, which is a type of colon cancer. You may be eligible if you are scheduled for treatments that aim to cure the cancer or if you've recently had surgery. Participants will need to provide blood samples for testing and agree to follow up with standard medical care after their treatment. The study is currently recruiting participants and is open to individuals of all genders, with the goal of improving our understanding of how to monitor and treat colorectal cancer effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years.
• • 2. Histological/cytological confirmation of colorectal adenocarcinoma.
• • 3. Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
• • 4. Ability to understand and the willingness to sign a written informed consent document.
• • 5. Willing to pursue standard of care surveillance post completion of curative therapies.
• • 6. Willing to provide blood samples for correlative research.
• Exclusion Criteria:
• • 1. Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
• • 2. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.